This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Care's 10 Dumbest Things, Part Two

Editor's Note: This year was a particularly absurd one for the health care industry. In light of that, we've expanded on our popular "Five Dumbest Things on Wall Street" to offer our "10 Dumbest Things in Health Care This Year." Part one examined the blunders of five big-cap names. Now, we look at the missteps of smaller companies.

1. WellCare's Silent Treatment

Silence isn't necessarily golden at tight-lipped WellCare (WCG - Get Report).

When 200 government agents swarmed the health insurer's Florida headquarters this fall, investors had a few questions. The company didn't answer them, though.

Instead, WellCare issued a press release mostly touting its "uninterrupted business operations" and, when pressed, followed up with a brief message from the CEO that offered much of the same -- except in audio form. Investors responded by sending WellCare's stock down 80% to a three-year low.

Enter the press, which apparently has a better way with words.

After clearly doing its homework, The Wall Street Journal published a convincing story based on an anonymous source who indicated that the WellCare investigation could prove narrow in scope and the potential fines modest in size. Other media outlets pounced on this new certainty by publishing their own versions of the truth. Wall Street analysts, rescued from the earlier information vacuum, eagerly chimed in with agreeable notes of their own.

WellCare's stock, suddenly attractive again, has rallied with few interruptions ever since.

Still, did publish a few minor items that -- for WellCare's sake -- might have been better left unsaid. First and foremost, WellCare investors have placed their trust in CEO Todd Farha, a "proven" leader who previously helped run two health insurers that weathered spectacular collapses . Moreover, Farha counts his own cousin as an "independent" director who enjoys the unique privilege of serving on every major committee that the board has. And he relies on his general counsel to double as chief compliance officer and keep the company in line.

But perhaps investors have nothing to fear. After all, WellCare runs a hard-core compliance operation reassuringly known as "The Trust Program." That program is designed to ensure that WellCare upholds all government laws so that FBI agents won't find any dirt when they happen to stop by for a raid.

WellCare talked about that program a lot before the company suddenly went mute. These days, however, the company relies on others to put comforting words in its mouth.

Dumb-O-Meter Score: 97. "We will tolerate nothing less than strict adherence to a code of conduct that appropriately educates and protects our members," WellCare CEO Todd Farha vowed just before Medicare cracked down on the company's marketing practices this summer. "I am confident that, with these new compliance enhancements, our overall compliance strategy will continue to be best-in-class."
1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
HMA $0.00 0.00%
MATR $3.34 -12.24%
THC $31.60 0.45%
WCG $95.32 0.45%
AAPL $93.24 -0.41%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs